Correction to: Anti-Müllerian hormone serum levels in systemic lupus erythematosus patients: influence of the disease severity and therapy on the ovarian reserve (Endocrine, (2019), 63, 2, (369-375), 10.1007/s12020-018-1783-1)

Angelina Barini, Paola Cattani, Elisa Gremese, Clara Di Mario, Valentina Varriano, Annamaria Paglionico, Gianfranco Ferraccioli, Barbara Tolusso

Risultato della ricerca: Contributo in rivistaArticolo in rivista

Abstract

Purpose Systemic lupus erythematosus (SLE) mainly affects childbearing age women and pharmacological treatments may negatively influence the ovarian reserve. Anti-Müllerian hormone (AMH) could be a good biomarker for ovarian reserve. Methods AMH serum levels were assessed in 86 consecutive SLE female patients with regular menstrual cycle compared with 44 aged matched healthy controls. Clinical and demographic characteristics, disease duration, pattern of organ involvement, and previous and current therapies were recorded. Results AMH levels were comparable between patients and controls (4.2 ± 3.1 ng/ml vs. 5.0 ± 3.1 ng/ml, p = 0.21). According to disease severity, AMH levels were lower in SLE patients with major organ involvement than in controls (3.8 ± 2.7 ng/ml vs. 5.0 ± 3.1 ng/ml, p = 0.08); no difference was found between SLE patients with mild organ involvement (4.5 ± 3.4 ng/ml) and controls (p = 0.43). Grouping patients based on the pharmacological treatments, AMH serum levels did not differ among SLE patients treated with antimalarials only (4.7 ± 3.3 ng/ml), conventional disease-modifying antirheumatic drugs (cDMARDs) only (4.8 ± 3.2 ng/ml), cDMARDs and antimalarials (3.9 ± 2.9 ng/ml) or cyclophosphamide (CYC) only (4.9 ± 3.9 ng/ml), compared to controls, but patients sequentially treated with cDMARDs and CYC, had significantly lower AMH serum levels than controls (p = 0.01). Conclusions SLE patients showed comparable AMH levels than controls, however, a reduction of the ovarian reserve was associated with sequentially therapy with CYC and cDMARDs and with the disease severity. AMH could be a sensitive and specific biomarker of ovarian reserve in SLE and it could be useful for therapeutic strategy and family planning.
Lingua originaleEnglish
pagine (da-a)405-405
Numero di pagine1
RivistaENDOCRINE
Volume63
DOI
Stato di pubblicazionePubblicato - 2019

Keywords

  • Anti-Müllerian hormone
  • systemic lupus erythematosus

Fingerprint

Entra nei temi di ricerca di 'Correction to: Anti-Müllerian hormone serum levels in systemic lupus erythematosus patients: influence of the disease severity and therapy on the ovarian reserve (Endocrine, (2019), 63, 2, (369-375), 10.1007/s12020-018-1783-1)'. Insieme formano una fingerprint unica.

Cita questo